Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 9;13:74. doi: 10.1186/s13045-020-00896-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 6 — Combined therapy with B10G5 and anti-PDL1 significantly decreases established B16-sMIC⁺ metastases. a Depiction of treatment scheme. B6/MICB mice received i.v. injection of 4 × 10⁵ B16F10-sMICB cells. At day 10, i.p. treatment was initiated with (1) control mIgG, (2) B10G5, (3) anti-PDL1, and (4) a combination of B10G5 and anti-PDL1. Antibodies were given by i.p. injection every 3 days in 200 μl sterile PBS. b Representative H&E sections of lungs of mice with metastatic B16-sMICB tumors. c Quantitation of micrometastasis in one lung section of all lobes. e, f Enhanced NK cell numbers, CD25 expression, and IFNγ production in draining LNs (two inguinal) of animals receiving combined treatment. Data obtained at day 21 of the experiment. *p < 0.05 as compared to the control group. Arrows show micrometastasis. **p < 0.05, combination therapy as compared to monotherapy